Empa long-term survival benefit

New analysis estimates the positive impact of empagliflozin on prolonging life expectancy in adults with type 2 diabetes and established cardiovascular diseaseSurvival estimates from the EMPA-REG OUTCOME ® trial data demonstrate potential long-term benefit of empagliflozin (marketed as Jardiance®) on life expectancy of adults with type 2 diabetes and cardiovascular disease1
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news